AbCellera Biologics (ABCL) Research & Development (2020 - 2026)

AbCellera Biologics has reported Research & Development for 7 years, with the latest figure at $46.7 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 9.8% year-over-year to $46.7 million; the trailing twelve-month figure through Mar 2026 stood at $191.0 million (up 12.04% YoY), and the FY2025 full-year result was $186.8 million, up 11.7% from the prior year.
• Research & Development for Q1 2026 stood at $46.7 million, down from $50.1 million in the prior quarter.
• The five-year high for Research & Development was $55.0 million in Q3 2025, with the low at $26.4 million in Q1 2022.
• Historically, Research & Development has averaged $40.3 million across 5 years, with a median of $40.9 million in 2024.
• Annual changes were most pronounced in 2022 — Research & Development jumped 113.46% — and 2024, when it slipped 25.38%.
• AbCellera Biologics' Research & Development stood at $28.2 million in 2022, then surged by 72.14% to $48.6 million in 2023, then retreated by 5.24% to $46.1 million in 2024, then grew by 8.72% to $50.1 million in 2025, then slipped by 6.85% to $46.7 million in 2026.
• The last three Research & Development figures came in at $46.7 million (Q1 2026), $50.1 million (Q4 2025), and $55.0 million (Q3 2025), per Business Quant data.